Denali Therapeutics Inc. (DNLI) Total liabilities 2017–2025
Denali Therapeutics Inc. (DNLI) total liabilities at each fiscal year-end, per SEC filings.
$131.1MFY2025 · since FY2017: $20.9M → $131.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $131.1M | -9.3% |
| FY2024 | $144.5M | +17.5% |
| FY2023 | $123.0M | -70.6% |
| FY2022 | $417.8M | -5.4% |
| FY2021 | $441.9M | -2.6% |
| FY2020 | $453.7M | +186.6% |
| FY2019 | $158.3M | +37.5% |
| FY2018 | $115.1M | +450.2% |
| FY2017 | $20.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Shareholders’ equityDNLI overview →